Biotech News

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Pacira BioSciences (PCRX)Pacira BioSciencesCommercial

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products’ Reach Across Selected Markets Within Its International Infrastructure Expands U.S. Innovative Medicines Commercial, Market Access, Medical Affairs and Global R&D

Related news

Pacira BioSciences

Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine...

Recent company news

Stock data

Close
24.76 USD
Market cap
875.49M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States